EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mitophagy activation by rapamycin enhances mitochondrial function and cognition in 5×FAD mice

Wenrong Zheng, Kualiang Li, Meihua Zhong, Kejun Wu, Lele Zhou, Jie Huang, Libin Liu, Zhou Chen

Behavioural Brain Research · 2024-04 · 463 · 114889

DOI: 10.1016/j.bbr.2024.114889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Behavioural Brain Research, 2024-04. Verfasst von Wenrong Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fujian Medical University, Fuzhou 350122, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Mitochondrial Diseases. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is the most prevalent form of dementia, characterized by severe mitochondrial dysfunction, which is an intracellular process that is significantly compromised in the early stages of AD. Mitophagy, the selective removal of damaged mitochondria, is a potential therapeutic strategy for AD. Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, augmented autophagy and mitigated cognitive impairment. Our study revealed that rapamycin enhances cognitive function by activating mitophagy, alleviating neuronal loss, and improving mitochondrial dysfunction in 5 ×FAD mice. Interestingly, the neuroprotective effect of rapamycin in AD were negated by treatment with 3-MA, a mitophagy inhibitor. Overall, our findings suggest that rapamycin ameliorates cognitive impairment in 5 ×FAD mice via mitophagy activation and its downstream PINK1-Parkin pathway, which aids in the clearance of amyloid-β (Aβ) and damaged mitochondria. This study reveals a novel mechanism involving mitophagy regulation underlying the therapeutic effect of rapamycin in AD. This study provides new insights and therapeutic targets for rapamycin in the treatment of AD. However, there are still some shortcomings in this topic; if we can further knock out the PINK1/Parkin gene in animals or use siRNA technology, we can further confirm the experimental results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMitochondrial DiseasesMiceAnimalsMitophagySirolimusMitochondriaCognitionUbiquitin-Protein LigasesMammals

Stichwörter der Autor:innen

5×FAD miceCognitive impairmentMitochondrial dysfunctionMitophagyRapamycin

Substanzen

SirolimusUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.
  • School of Pharmacy, Fujian Medical University, Fuzhou 350122, China; Fujian Institute of Microbiology, Fuzhou 350007, China.
  • Department of Endocrinology and Metabolism, Fujian Medical University Union Hospital, Fuzhou 350001, China.
  • Fujian Institute of Microbiology, Fuzhou 350007, China.
  • School of Pharmacy, Fujian Medical University, Fuzhou 350122, China. Electronic address: chenzhou@fjmu.edu.cn.

Zitieren

APA

Zheng, W., Li, K., Zhong, M., Wu, K., Zhou, L., Huang, J., Liu, L., & Chen, Z. (2024). Mitophagy activation by rapamycin enhances mitochondrial function and cognition in 5×FAD mice. Behavioural Brain Research, 463, 114889. https://doi.org/10.1016/j.bbr.2024.114889

Vancouver

Zheng W, Li K, Zhong M, Wu K, Zhou L, Huang J, et al. Mitophagy activation by rapamycin enhances mitochondrial function and cognition in 5×FAD mice. Behavioural Brain Research. 2024;463:114889. doi:10.1016/j.bbr.2024.114889

BibTeX
@article{Zheng2024,
  author = {Zheng, Wenrong and Li, Kualiang and Zhong, Meihua and Wu, Kejun and Zhou, Lele and Huang, Jie and Liu, Libin and Chen, Zhou},
  title = {Mitophagy activation by rapamycin enhances mitochondrial function and cognition in 5×FAD mice},
  journal = {Behavioural Brain Research},
  year = {2024},
  volume = {463},
  pages = {114889},
  doi = {10.1016/j.bbr.2024.114889}
}
Kostenlos starten →